# Perseus (NCT03710603)

> Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03710603
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Stichting European Myeloma Network
- Conditions: Multiple Myeloma
- Interventions: Daratumumab; Velcade; Lenalidomide; dexamethasone
- Enrollment: 709
- Primary outcome: Progression Free Survival (PFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 255
- X threads: 185
- Podcasts: 111
- X videos: 3
- Bluesky threads: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=perseus-nct03710603

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03710603", "email": "<work email>"}; the inbox owner confirms by the emailed link.